A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INNO-406 in Adult Patients With Imatinib-Resistant or Intolerant Philadelphia Chromosome-Positive (Ph+) Leukemias

Trial Profile

A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INNO-406 in Adult Patients With Imatinib-Resistant or Intolerant Philadelphia Chromosome-Positive (Ph+) Leukemias

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2011

At a glance

  • Drugs Bafetinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2011 Results were reported in November 2008, according to a CytRx Corporation media release
    • 27 Jan 2009 Results will be published in a peer-reviewed journal in quarter three of this year, as reported by CytRx in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top